Reviewing Alector Inc. (ALEC)’s and Otonomy Inc. (NASDAQ:OTIC)’s results

This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in Alector Inc. (NASDAQ:ALEC) and Otonomy Inc. (NASDAQ:OTIC). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alector Inc. 17 -0.36 29.68M -0.40 0.00
Otonomy Inc. 2 -0.08 24.46M -1.66 0.00

Table 1 demonstrates Alector Inc. and Otonomy Inc.’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Alector Inc. 179,769,836.46% 0% 0%
Otonomy Inc. 1,029,461,279.46% -60.1% -48.1%

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Alector Inc. and Otonomy Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alector Inc. 0 0 1 3.00
Otonomy Inc. 0 0 1 3.00

$28 is Alector Inc.’s consensus target price while its potential upside is 42.71%. Meanwhile, Otonomy Inc.’s consensus target price is $8, while its potential upside is 210.08%. Based on the analysts view we can conclude, Otonomy Inc. is looking more favorable than Alector Inc.

Insider and Institutional Ownership

Alector Inc. and Otonomy Inc. has shares owned by institutional investors as follows: 59.1% and 61.6%. 8.1% are Alector Inc.’s share owned by insiders. Comparatively, insiders own roughly 0.28% of Otonomy Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alector Inc. 6.24% 11.86% 7.1% 0% 0% 17.33%
Otonomy Inc. 5.58% 9.23% 6.37% 39.9% -13.94% 53.51%

For the past year Alector Inc.’s stock price has smaller growth than Otonomy Inc.


On 6 of the 11 factors Otonomy Inc. beats Alector Inc.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer’s ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.